Your co-pilot for clinical monitoring
Medable’s CRA Agent is an AI-driven solution that automates and optimizes clinical trial monitoring by proactively identifying and prioritizing site risks, generating comprehensive pre-visit summaries, and providing actionable recommendations to enhance trial oversight and compliance.
We estimate that CRA agents can take on up to 90% of the tactical and administrative work the CRA handles on a daily basis — from sending site-specific emails and reminders to tracking responses and updating systems. That means we can focus our time on the strategic decisions that move trials forward, while standardizing and streamlining the tasks that used to consume most of our day.
Connected monitoring across systems
Perceive signals across the entire clinical data ecosystem by unifying CTMS, RTSM, EDC, labs, consent, and safety into one view. Turn manual checks into automated insights, instantly highlighting which sites are on track and where intervention is needed, saving valuable time, system-hopping, and manual data compilation.
Human-in-the-loop oversight
Easily identify risks and recommendations for best-next actions tied to your protocol, consent, and regulatory requirements. Stay assured with a transparent reasoning trail thatshows why each step is advised, enabling CRAs to collaborate confidently with sites, improve decision-making, enhance their compliance, all while freeing CRAs to focus on engagement and site-specific challenges.
Automated administrative tasks
Take advantage of automated routine tasks like drafting queries, sending emails, and updating CTMS/eTMF — always with human CRA oversight. Close the loop between planning and execution with real-time tracking that reduces administrative burden, ensures data consistency, and accelerates trial progress.
The latest from Knowledge Centers
Paper COAs in 2026? It’s not “cheaper,” it’s riskier
eCOA’s time has come. The market is currently estimated to be worth $2.3 billion, with projections showing it reaching nearly $5 billion by 2030. Despite this, paper still plays a prominent role for some clinical trials today.
At first glance, paper may seem simple and familiar, even economical. However, in today’s regulatory and operational environment, paper COAs are not a risk averse choice when held to the standards of what sponsors, CROs, and regulators are looking for trial data to prove.
Innovation Evidence : A Tufts CSDD workshop
In the five years since the pandemic, decentralized trial elements have solidified their status in medical product development.
Trials with decentralized elements have moved past the “pilot” phase. The question is no longer whether we can operationalize decentralized trial components, it's whether we’re doing it thoughtfully at the pace patients deserve. Our industry is ready to optimize the elements for the trial based on available evidence.
That’s exactly why Medable, in collaboration with and facilitated by the Tufts Center for the Study of Drug Development (Tufts CSDD), has launched the Innovation Evidence Workshop series.
Last November, the inaugural, invitation-only workshop brought leaders from 20 pharmaceutical, biotech, and CRO organizations together in Boston, with representation from the U.S. Food and Drug Administration, Harvard MRCT Center, Tufts CSDD, and Medable.
What happened at Scope Summit 2026
To many, the SCOPE Summit is the year’s “newsroom,” setting the stage for what hot topics and driving forces will dominate the coming year.
With this year’s conference winding down, we’re once again offering a glimpse into the evolving operational and technological conversations shaping the future of trials with our recap below.
Eliminate clinical trial white space with the right AI strategy
It has become clear that our industry has reachedthe limits of human-only clinical development. As clinical trials have become increasingly complex, the endeavors that people alone can perform are no longer sufficient to generate the momentum needed to address the growing burden of human disease. This has led to longer drug development timelines and significant delays for patients. One large are of lost time is “white space,” definied simply as unproductive time caused by manual, sequential processes and fragmented data systems. Thankfully, a solution lies in agentic AI and its abilities to perform series of tasks.